Viking Therapeutics' GLP-1 Drug VK2735 Shows Weight-Loss Promise in Trial
Viking Therapeutics reports positive clinical trial results for VK2735, a monthly GLP-1/GIP drug that could challenge Eli Lilly's Zepbound.
Viking Therapeutics sent its stock surging after announcing that its experimental weight-loss drug VK2735 successfully helped patients maintain weight loss in a clinical trial, with results holding even for participants receiving the injection just once a month — a dosing schedule that could set it apart from rivals already on the market.
VK2735 is a dual GLP-1/GIP receptor agonist, placing it in the same mechanistic class as Eli Lilly's Zepbound, one of the best-selling obesity treatments currently available. By targeting two hormonal pathways simultaneously, drugs in this category tend to deliver stronger weight-reduction results than earlier single-receptor medications, making them highly sought after by patients and investors alike.
Read more JPMorgan Admits Oil Price Outlook Uncertain Amid Iran Tensions →
The monthly dosing finding is particularly significant from a commercial standpoint. Current blockbuster GLP-1 therapies typically require weekly injections, and a once-monthly schedule could meaningfully improve patient adherence and convenience — two factors that pharmaceutical analysts consider critical to long-term market penetration in the obesity drug space.
Viking's stock rallied sharply on the news, reflecting Wall Street's appetite for any credible challenger to Eli Lilly and Novo Nordisk, which currently dominate the obesity treatment landscape. If VK2735 advances successfully through later-stage trials and regulatory review, it could inject fresh competition into a market projected to generate tens of billions of dollars in annual revenue within the decade.
The obesity drug race is accelerating, and Viking's latest data positions VK2735 as a legitimate contender worth watching as the company pursues further development milestones. Continue reading at MarketWatch.com
